Recce Pharmaceuticals Ltd
RECEF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $7,509 | $6,850 | $4,365 | $3,085 |
| % Growth | 9.6% | 56.9% | 41.5% | – |
| Cost of Goods Sold | $10,446 | $7,217 | $217 | $188 |
| Gross Profit | -$2,937 | -$367 | $4,148 | $2,897 |
| % Margin | -39.1% | -5.4% | 95% | 93.9% |
| R&D Expenses | $10,243 | $0 | $7,167 | $6,224 |
| G&A Expenses | $8,462 | $5,870 | $4,113 | $2,373 |
| SG&A Expenses | $9,700 | $7,112 | $5,231 | $3,367 |
| Sales & Mktg Exp. | $1,238 | $1,241 | $1,118 | $994 |
| Other Operating Expenses | $0 | $0 | $4,282 | $1,532 |
| Operating Expenses | $19,943 | $14,154 | $17,108 | $13,963 |
| Operating Income | -$22,880 | -$22,051 | -$17,326 | -$14,150 |
| % Margin | -304.7% | -321.9% | -396.9% | -458.7% |
| Other Income/Exp. Net | $1,452 | -$516 | $4,248 | -$4,423 |
| Pre-Tax Income | -$21,428 | -$22,568 | -$17,389 | -$14,071 |
| Tax Expense | $0 | -$4,906 | -$4,311 | -$3,085 |
| Net Income | -$21,428 | -$17,662 | -$13,077 | -$10,986 |
| % Margin | -285.4% | -257.8% | -299.6% | -356.1% |
| EPS | -0.09 | -0.1 | -0.074 | -0.063 |
| % Growth | 9.3% | -34% | -19% | – |
| EPS Diluted | -0.09 | -0.1 | -0.074 | -0.063 |
| Weighted Avg Shares Out | 236,976 | 177,101 | 175,714 | 175,871 |
| Weighted Avg Shares Out Dil | 236,975 | 177,100 | 175,714 | 175,871 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $187 | $66 | $91 |
| Interest Expense | $0 | $847 | $183 | $12 |
| Depreciation & Amortization | $72 | $367 | $217 | $188 |
| EBITDA | -$20,335 | -$21,354 | -$16,988 | -$10,796 |
| % Margin | -270.8% | -311.7% | -389.2% | -350% |